SEARCH

SEARCH BY CITATION

References

  • 1
    McAlister VC, Peltekian KM, Malatjalian DH, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 8: 7018.
  • 2
    Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003; 35: S193200.
  • 3
    Murgia M, Jordan S, Kahan B. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 20916.
  • 4
    Gilroy RK, McCashland TM, Mukherjee S, et al. Analysis of sirolimus in liver transplantation, the effect on chronic renal dysfunction, adverse events and allograft rejection. Hepatology 2002; 36: 185A.
  • 5
    Chang GJ, Mahanty HD, Quan D, et al. Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000; 6: 73440.
  • 6
    Nair S, Verma S, Thuluvath PJ. Pre-transplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35: 117985.
  • 7
    Pridohl O, Heinemann K, Hartwig T, et al. Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. Transplant Proc 2001; 33: 3229.
  • 8
    Kniepeiss D, Iberer F, Grasser B, et al. Sirolimus in patients after liver transplantation. Transplant Proc 2003; 35: 8156.
  • 9
    Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 50514.
  • 10
    Poordad F, Flores P, Tran T, et al. Failure of sirolimus to impact major outcome variables in tacrolimus-based immunosuppression regimens in liver transplant recipients. Hepatology 2002; 36: 186A.
  • 11
    Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 1269.
  • 12
    Gee I, Watson CJ, Alexander GJ, et al. Sirolimus improves long-term renal function after liver transplantation. Hepatology 2002; 36: 186A.
  • 13
    Cotterell AH, Fisher RA, King AL, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002; 16: 4951.
  • 14
    Dhir R, Quinn MK, Dennis V, et al. Conversion from a calcineurin inhibitor to sirolimus in liver transplant recipients with chronic renal insufficiency. Hepatology 2002; 36: 187A.
  • 15
    Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003; 9: 4638.
  • 16
    Hong JC, Kahan BD. Sirolimus induced thrombocytopenia and leucopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000; 69: 208590.
  • 17
    Montalbano M, Neff GW, Yamashiki N, et al. Sirolimus related side effects in liver transplanted recipients. Transplantation 2004; 78: 2648.
  • 18
    Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103: 1925.
  • 19
    Guilbeau JM. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002; 36: 13915.
  • 20
    Trotter JF, Wachs M, Bak T, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001; 7: 4018.
  • 21
    Firpi RJ, Tran TT, Flores P, et al. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther 2004; 19: 10339.